Integra LifeSciences Holdings (IART) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.009x

Based on the latest financial reports, Integra LifeSciences Holdings (IART) has a cash flow conversion efficiency ratio of 0.009x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($9.80 Million) by net assets ($1.04 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see IART stock market capitalisation for the company's overall valuation and market capitalisation.

Integra LifeSciences Holdings - Cash Flow Conversion Efficiency Trend (1995–2025)

This chart illustrates how Integra LifeSciences Holdings's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Integra LifeSciences Holdings Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Integra LifeSciences Holdings ranked by their cash flow conversion efficiency. Explore IART cash to earnings ratio to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Ribo Fashion Group Co Ltd
SHG:603196
0.024x
United Corporations Limited
TO:UNC
0.004x
Lanzhou LS Heavy Equipment Co
SHG:603169
-0.003x
Gansu Yasheng Industrial Group Co Ltd
SHG:600108
0.005x
Hunan Yujing Machinery Co Ltd Class A
SHE:002943
0.113x
Taiwan Hon Chuan Enterprise Co Ltd
TW:9939
0.099x
Cadre Holdings Inc
NYSE:CDRE
0.067x
Universal Technical Institute Inc
NYSE:UTI
0.030x

Annual Cash Flow Conversion Efficiency for Integra LifeSciences Holdings (1995–2025)

The table below shows the annual cash flow conversion efficiency of Integra LifeSciences Holdings from 1995 to 2025. View IART share price today for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $1.04 Billion $50.38 Million 0.048x -42.33%
2024-12-31 $1.55 Billion $129.38 Million 0.084x -5.01%
2023-12-31 $1.59 Billion $139.96 Million 0.088x -39.86%
2022-12-31 $1.80 Billion $264.47 Million 0.147x -20.96%
2021-12-31 $1.68 Billion $312.43 Million 0.185x +37.82%
2020-12-31 $1.51 Billion $203.83 Million 0.135x -17.63%
2019-12-31 $1.42 Billion $231.43 Million 0.163x +12.55%
2018-12-31 $1.38 Billion $199.68 Million 0.145x +21.93%
2017-12-31 $962.31 Million $114.54 Million 0.119x -14.14%
2016-12-31 $839.67 Million $116.41 Million 0.139x +10.26%
2015-12-31 $751.44 Million $94.48 Million 0.126x +11.45%
2014-12-31 $704.32 Million $79.46 Million 0.113x +41.94%
2013-12-31 $670.18 Million $53.27 Million 0.079x -29.91%
2012-12-31 $517.77 Million $58.72 Million 0.113x -46.45%
2011-12-31 $492.64 Million $104.33 Million 0.212x +0.29%
2010-12-31 $499.96 Million $105.57 Million 0.211x -34.41%
2009-12-31 $444.88 Million $143.24 Million 0.322x +55.33%
2008-12-31 $350.21 Million $72.59 Million 0.207x +14.79%
2007-12-31 $260.43 Million $47.03 Million 0.181x -25.42%
2006-12-31 $296.16 Million $71.70 Million 0.242x +23.43%
2005-12-31 $289.82 Million $56.85 Million 0.196x +54.92%
2004-12-31 $307.82 Million $38.98 Million 0.127x -2.37%
2003-12-31 $268.53 Million $34.83 Million 0.130x +0.39%
2002-12-31 $247.60 Million $31.98 Million 0.129x +67.89%
2001-12-31 $204.06 Million $15.70 Million 0.077x +183.43%
2000-12-31 $53.78 Million $-4.96 Million -0.092x -240.18%
1999-12-31 $38.00 Million $2.50 Million 0.066x +121.08%
1998-12-31 $31.40 Million $-9.80 Million -0.312x -41.43%
1997-12-31 $35.80 Million $-7.90 Million -0.221x -27.99%
1996-12-31 $46.40 Million $-8.00 Million -0.172x +46.43%
1995-12-31 $17.40 Million $-5.60 Million -0.322x --

About Integra LifeSciences Holdings

NASDAQ:IART USA Medical Devices
Market Cap
$1.18 Billion
Market Cap Rank
#8235 Global
#2403 in USA
Share Price
$15.22
Change (1 day)
+0.79%
52-Week Range
$8.90 - $19.85
All Time High
$76.63
About

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural … Read more